Phase 1 Clinical Trials of MK-7602: A Promising New Chapter in the Fight Against Malaria

⏱ In 30 Seconds

✓ MK-7602 is a first-in-class experimental antimalarial drug jointly developed by WEHI and MSD.
✓ It blocks two essential malaria parasite enzymes, plasmepsin IX and plasmepsin X.
✓ Phase 1 studies found that MK-7602 was generally well tolerated in healthy volunteers and reached blood concentrations predicted to have antimalarial activity.
✓ The results mark an important transition from nearly a decade of laboratory research to early clinical development.

From Laboratory Discovery to Human Trials

For decades, malaria parasites have repeatedly evolved resistance to medicines that once transformed global malaria control, creating an urgent need for drugs that attack the parasite through entirely different biological mechanisms.

In March 2026, researchers at the Walter and Eliza Hall Institute of Medical Research (WEHI) reported an important milestone in that effort. Early clinical trial results showed that the experimental antimalarial drug MK-7602 was generally well tolerated in healthy volunteers and achieved blood concentrations predicted to kill malaria parasites effectively.

Phase 1 clinical trials are designed primarily to evaluate safety, tolerability and how a drug behaves inside the human body. They do not yet prove that a medicine can cure malaria.

Even so, the successful completion of first-in-human testing marked a major step for this first-in-class dual plasmepsin inhibitor. It represented the transition of nearly a decade of laboratory research into the earliest stage of clinical medicine.

What Is MK-7602?

MK-7602 is a first-in-class dual plasmepsin inhibitor jointly developed by WEHI and MSD, known as Merck & Co. in the United States and Canada.

Unlike antimalarial medicines that act through other established parasite pathways, MK-7602 simultaneously inhibits two essential malaria enzymes: plasmepsin IX (PMIX) and plasmepsin X (PMX).

These enzymes are involved in several crucial stages of the malaria parasite’s life cycle, including invasion of human cells, growth within red blood cells and transmission-related processes.

By blocking both enzymes at the same time, researchers hope to create a treatment that is more difficult for malaria parasites to evade through a single genetic change.

This dual-targeting strategy may therefore provide a higher barrier to the emergence of drug resistance, although that possibility must still be confirmed through further laboratory and clinical investigation.

The Story Behind the Discovery

MK-7602 emerged from nearly a decade of collaboration between Professor Alan Cowman and colleagues at WEHI and scientists at MSD.

The project began with high-throughput compound screening at Australia’s National Drug Discovery Centre, located at WEHI.

Researchers screened large collections of chemical compounds to identify molecules capable of interfering with essential malaria parasite biology.

After promising chemical starting points were identified, medicinal chemists refined the compounds while biologists investigated how they affected the parasite.

This close partnership between academic researchers and pharmaceutical scientists eventually produced MK-7602, a drug candidate with activity against both Plasmodium falciparum and Plasmodium vivax.

These two parasite species are responsible for a large proportion of the global malaria burden.

How Does MK-7602 Work?

Malaria parasites must invade host cells, multiply inside them and escape before infecting new cells.

Plasmepsin IX and plasmepsin X help the parasite complete critical steps in these processes.

MK-7602 is designed to inhibit both enzymes simultaneously. By disrupting these essential biological functions, the drug may prevent parasites from successfully invading, developing and continuing their life cycle.

This mechanism is especially important because it differs from those used by many existing antimalarial medicines.

A genuinely new mechanism of action can provide another option when parasites become less sensitive to established drugs.

What Happened in the Phase 1 Trials?

The Phase 1 clinical programme included studies evaluating single ascending doses and multiple ascending doses in healthy adult volunteers.

Researchers gradually increased the amount of MK-7602 given to participants while monitoring safety, tolerability and pharmacokinetics.

Pharmacokinetics describes how a drug is absorbed, distributed, processed and removed by the body.

MK-7602 was generally well tolerated.
No major safety concerns were identified in the reported studies.
The most commonly reported adverse event was mild headache.
Drug exposure reached levels predicted to provide antimalarial activity.

The studies also produced important information about how long MK-7602 remained in the bloodstream and how its concentration changed after single and repeated doses.

These findings will help researchers select appropriate doses for future clinical trials designed to evaluate antimalarial activity more directly.

Why This Discovery Still Matters

Resistance has repeatedly undermined antimalarial medicines, creating a continuing need for drugs that attack the parasite in new ways.

MK-7602 is important because it simultaneously targets two essential parasite enzymes, plasmepsin IX and plasmepsin X. Laboratory research suggests that this dual-targeting strategy may create a higher barrier to resistance, although that will need to be confirmed in further studies.

The development of MK-7602 also demonstrates the value of long-term fundamental research. Scientists first had to understand the parasite’s biology before plasmepsins could become drug targets and a compound could be developed to block them.

Recognition

The significance of this work has also received national recognition.

In 2026, the WEHI-led research team behind the programme was named a finalist for an Australian Museum Eureka Prize, one of Australia’s best-known science awards.

The recognition highlights a long scientific journey that progressed from fundamental discoveries in malaria biology to the development of a promising new antimalarial drug candidate.

A Personal Note

As a researcher, there is another reason why I find the MK-7602 story particularly interesting: it is a reminder of the importance of good, reproducible science.

Not every exciting experimental result stands the test of time. Findings that look convincing in a paper do not always prove reproducible when other researchers try to build on them.

I also know how difficult and long the journey can be from in vitro experiments to animal models and, eventually, human clinical trials. At every stage, the science has to withstand another level of testing before the next step becomes possible.

That is why I have great respect for the research team that has brought MK-7602 this far. Reaching a Phase 1 clinical trial does not guarantee that a drug will ultimately succeed, but getting there after years of laboratory and preclinical research is a big achievement in itself.

As a former colleague and long-time friend, I would also have loved to see Alan Yap, who completed his PhD in the Cowman lab, as part of this remarkable research journey. He has since followed his own path and is doing work he enjoys, but it would still have been nice to see an old friend among the team.

I sincerely hope MK-7602 continues to progress successfully through clinical development and, one day, becomes another medicine that helps us fight malaria.

What Comes Next?

Following the Phase 1 safety studies, the next stage is to determine whether MK-7602 can produce the expected antimalarial effects in humans.

Future studies are expected to evaluate its activity against controlled Plasmodium falciparum infection and measure how quickly the drug clears parasites from the bloodstream.

Researchers will also need to determine the most effective dose, assess whether the drug remains safe in larger and more diverse groups of participants and investigate how it could be combined with another antimalarial medicine.

Combination therapy is particularly important in malaria because using two drugs with different mechanisms can reduce the risk that resistant parasites will survive treatment.

Many experimental medicines do not progress beyond early clinical trials, and Phase 1 results cannot predict whether MK-7602 will ultimately become an approved treatment.

But MK-7602 has already crossed an important boundary: from a laboratory idea based on malaria parasite biology to an experimental medicine administered to people. Its journey shows how curiosity-driven research, drug discovery, medicinal chemistry and clinical development can come together to create a new therapeutic strategy.

thebiostories

MK-7602 Phase 1 Clinical Trial Results: WEHI's New Antimalarial Drug Reaches a Major Milestone